Radiofrequency as the New Opportunity in Treating Overactive Bladder and Urge Urinary Incontinence—A Single-Arm Pilot Study
Abstract
:1. Introduction
2. Methods
2.1. Criteria for Inclusion in This Study
2.2. Exclusion Criteria for This Study
2.3. Radiofrequency in the Treatment of Urinary Incontinence
2.4. Statistics
3. Results
- Mild symptoms: 0–3;
- Moderate symptoms: 4–7;
- Severe symptoms: 8–11;
- Very severe symptoms: 12–16.
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Corcos, J.; Przydacz, M.; Campeau, L.; Gray, G.; Hickling, D.; Honeine, C.; Radomski, S.B.; Stothers, L.; Wagg, A. CUA guideline on adult overactive bladder. Can. Urol. Assoc. J. 2017, 11, 142–173. [Google Scholar] [CrossRef] [PubMed]
- Haylen, B.T.; De Ridder, D.; Freeman, R.M.; Swift, S.E.; Berghmans, B.; Lee, J.; Monga, A.; Petri, E.; Rizk, D.E.; Sand, P.K.; et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol. Urodyn. 2010, 29, 4–20. [Google Scholar] [CrossRef]
- Abrams, P.; Cardozo, L.; Fall, M.; Griffiths, D.; Rosier, P.; Ulmsten, U.; Van Kerrebroeck, P.; Victor, A.; Wein, A. The standardisation of terminology of lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Neurourol. Urodyn. 2021, 21, 167–178. [Google Scholar] [CrossRef] [PubMed]
- Milsom, I.; Coyne, K.S.; Nicholson, S.; Kvasz, M.; Chen, C.I.; Wein, A.J. Global prevalence and economic burden of urgency urinary incontinence: A systematic review. Eur. Urol. 2014, 65, 79–95. [Google Scholar] [CrossRef] [PubMed]
- Madhuvrata, P.; Cody, J.D.; Ellis, G.; Herbison, G.P.; Hay-Smith, E.J. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst. Rev. 2012, 1, CD005429. [Google Scholar] [CrossRef]
- Khullar, V.; Chapple, C.; Gabriel, Z.; Dooley, J.A. The effects of antimuscarinics on health-related quality of life in overactive bladder: A systematic review and meta-analysis. Urology 2006, 68, 38–48. [Google Scholar] [CrossRef]
- Chapple, C.R.; Khullar, V.; Gabriel, Z.; Muston, D.; Bitoun, C.E.; Weinstein, D. The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis. Eur. Urol. 2008, 54, 543–562. [Google Scholar] [CrossRef]
- Cui, Y.; Zong, H.; Yang, C.; Yan, H.; Zhang, Y. The efficacy and safety of mirabegron in treating OAB: A systematic review and meta-analysis of phase III trials. Int. Urol. Nephrol. 2014, 46, 275–284. [Google Scholar] [CrossRef]
- Buser, N.; Ivic, S.; Kessler, T.M.; Kessels, A.G.; Bachmann, L.M. Efficacy and adverse events of antimuscarinics for treating overactive bladder: Network meta-analyses. Eur. Urol. 2012, 62, 1040–1060. [Google Scholar] [CrossRef]
- Gray, S.L.; Anderson, M.L.; Dublin, S.; Hanlon, J.T.; Hubbard, R.; Walker, R.; Yu, O.; Crane, P.K.; Larson, E.B. Cumulative Use of Strong Anticholinergics Medications and Incident Dementia. JAMA Intern. Med. 2015, 175, 401–407. [Google Scholar] [CrossRef]
- Abrams, P.; Kelleher, C.; Staskin, D.; Kay, R.; Martan, A.; Mincik, I.; Newgreen, D.; Ridder, A.; Paireddy, A.; van Maanen, R. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, Phase II study (SYMPHONY). World J. Urol. 2016, 35, 827–838. [Google Scholar] [CrossRef] [PubMed]
- Drake, M.J.; Chapple, C.; Esen, A.A.; Athanasiou, S.; Cambronero, J.; Mitcheson, D.; Herschorn, S.; Saleem, T.; Huang, M.; Siddiqui, E.; et al. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). Eur. Urol. 2016, 70, 136–145. [Google Scholar] [CrossRef] [PubMed]
- Rodriguez, L.J.; Pinero, M.E. Use of an Evolution in Tecartherapy for Muscle Improvement and Treatment of Sports Injuries. In Recent Advances in Sport Science; InTech Open: London, UK, 2021. [Google Scholar] [CrossRef]
- Pinheiro, C.; Costa, T.; de Jesus, R.A.; Campos, R.; Brim, R.; Teles, A.; Boas, A.V.; Lordêlo, P. Intravaginal nonablative radiofrequency in the treatment of genitourinary syndrome of menopause symptoms: A single-arm pilot study. BMC Womens Health 2021, 21, 379. [Google Scholar] [CrossRef] [PubMed]
- Coyne, K.S.; Wein, A.; Nicholson, S.; Kvasz, M.; Chen, C.-I.; Milsom, I. Economic Burden of Urgency Urinary Incontinence in the United States: A Systematic Review. J. Manag. Care Pharm. 2014, 20, 130–140. [Google Scholar] [CrossRef] [PubMed]
- Fontaine, C.; Papworth, E.; Pascoe, J.; Hashim, H. Update on the management of overactive bladder. Ther. Adv. Urol. 2021, 13, 17562872211039034. [Google Scholar] [CrossRef] [PubMed]
- Araklitis, G.; Robinson, D.; Cardozo, L. Cognitive Effects of Anticholinergic Load in Women with Overactive Bladder. Clin. Interv. Aging 2020, 15, 1493–1503. [Google Scholar] [CrossRef]
- Kay, G.G.; Granville, L.J. Antimuscarinic agents: Implications and concerns in the management of overactive bladder in the elderly. Clin. Ther. 2005, 27, 127–138. [Google Scholar] [CrossRef] [PubMed]
- Griebling, T.L.; Campbell, N.L.; Mangel, J.; Staskin, D.; Herschorn, S.; Elsouda, D.; Schermer, C.R. Effect of mirabegron on cognitive function in elderly patients with overactive bladder: Mo CA results from a Phase 4 randomized, placebo-controlled study (PILLAR). BMC Geriatr. 2020, 20, 109. [Google Scholar] [CrossRef]
- Staskin, D.; Frankel, J.; Varano, S.; Kennelly, M.; Newman, D.K.; Rosenberg, M.T.; Shortino, D.D.; Jankowich, R.A.; Mudd, P.N., Jr. Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial. Int. J. Clin. Pract. 2022, 2022, 6475014. [Google Scholar] [CrossRef]
- Wagg, A.; Staskin, D.; Engel, E.; Herschorn, S.; Kristy, R.M.; Schermer, C.R. Efficacy, safety, and tolerability of mirabegron in patients aged ≥65 year with overactive bladder wet: A phase IV, double-blind, randomised, placebo-controlled study (PILLAR). Eur. Urol. 2020, 77, 211–220. [Google Scholar] [CrossRef]
- Wesnes, A.K.; Edgar, C.; Tretter, R.N.; Bolodeoku, J. Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. Expert Opin. Drug Saf. 2009, 8, 615–626. [Google Scholar] [CrossRef] [PubMed]
- Kay, G.; Crook, T.; Rekeda, L.; Lima, R.; Ebinger, U.; Arguinzoniz, M.; Steel, M. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur. Urol. 2006, 50, 317–326. [Google Scholar] [CrossRef] [PubMed]
- Wagg, A.; Arumi, D.; Herschorn, S.; Cuesta, J.A.; Haab, F.; Ntanios, F.; Carlsson, M.; Oelke, M. A pooled analysis of the efficacy of fesoterodine for the treatment of overactive bladder, and the relationship between safety, co-morbidity and polypharmacy in patients aged 65 years or older. Age Ageing 2017, 46, 620–626. [Google Scholar] [CrossRef] [PubMed]
- Kay, G.; Kardiasmenos, K.; Crook, T. Differential effects of the antimuscarinic agents tolterodine tartrate ER and oxybutyin chloride ER on recent memory in older subjects. In Proceedings of the 36th meeting of the International Continence Society, Christchurch, New Zealand, 27 November–1 December 2006. [Google Scholar]
- Franić, D.; Fistonić, I. Laser therapy in the treatment of female urinary incontinence and genitourinary syndrome of menopause: An update. BioMed Res. Int. 2019, 2019, 1576359. [Google Scholar] [CrossRef] [PubMed]
- Franić, D.; Fistonić, I.; Franić-Ivanišević, M.; Perdija, Ž.; Križmarić, M. Pixel CO2 Laser for the Treatment of Stress Urinary Incontinence: A Prospective Observational Multicenter Study. Lasers Surg. Med. 2020, 53, 514–520. [Google Scholar] [CrossRef]
- Millheiser, L.S.; Pauls, R.N.; Herbrst, S.J.; Chen, B.H. Radiofrequency treatment of vaginal laxity after vaginal delivery: Nonsurgical vaginal tightening. J. Sex Med. 2010, 7, 3088–3095. [Google Scholar] [CrossRef]
- Allan, B.B.; Bell, S.; Husarek, K. A 12-month feasibility study to investigate the effectiveness of cryogen-cooled monopolar radiofrequency treatment for female stress urinary incontinence. Can. Urol. Assoc. J. 2020, 14, E313–E318. [Google Scholar] [CrossRef]
- Lordelo, P.; Boas, A.V.; Sodré, D.; Lemos, A.; Tozetto, S.; Brasil, C. New concept for treating female stress urinary incontinence with radiofrequency. Int. Braz. J. Urol. 2017, 43, 896–902. [Google Scholar] [CrossRef]
- Usman Ali, M.; Nai-Kuen Fong, K.; Kannan PBello, U.M.; Kranz, G. Effects of nonsurgical, minimally or noninvasive therapies for urinary incontinence due to neurogenic bladder: A systematic review and meta-analysis. Ther. Adv. Chronic. Dis. 2022, 13, 1–17. [Google Scholar] [CrossRef]
- Lin, Z.-X.; Chan, N.H.T.; Kwan, Y.-K.; Chan, Y.T.; Zhang, H.; Tam, K.-Y.S.; Lai, M.K.; Lee, C.-K.; Ngan, K.; Tsoi, S.Y.Y.; et al. A randomized controlled trial to assess the effectiveness and safety of acupuncture for overactive bladder: A study in Hong Kong population. Chin. Med. 2020, 15, 108. [Google Scholar] [CrossRef]
Mean ± SD or n (%) | Min–Max | |
---|---|---|
Age | 57.9 ± 13.0 | 38–71 |
Age categories | ||
<50 years | 5 (26.3%) | |
50–59 years | 5 (26.3%) | |
≥60 years | 9 (47.4%) | |
BMI | 28.5 ± 3.9 | 21–35 |
BMI categories | ||
BMI < 25 | 2 (10.5%) | |
BMI 25–29.99 | 9 (47.4%) | |
BMI ≥ 30 | 8 (42.1%) | |
Maternal history—parity | 2.37 ± 1.21 | 1–6 |
Grade before the Therapy | Grade after the Therapy | |||
---|---|---|---|---|
n = 19 | % | n = 14 | % | |
Mild | 2 | 10.5 | 6 | 42.9 |
Moderate | 4 | 21.1 | 7 | 50.0 |
Severe | 12 | 63.2 | 1 | 7.1 |
Very severe | 1 | 5.3 | 0 | 0.0 |
Missing | 0 | 5 | ||
Total | 19 | 100.0 | 19 | 100.0 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Franić, D.; Franić Ivanišević, M.; Verdenik, I. Radiofrequency as the New Opportunity in Treating Overactive Bladder and Urge Urinary Incontinence—A Single-Arm Pilot Study. Medicina 2024, 60, 197. https://doi.org/10.3390/medicina60020197
Franić D, Franić Ivanišević M, Verdenik I. Radiofrequency as the New Opportunity in Treating Overactive Bladder and Urge Urinary Incontinence—A Single-Arm Pilot Study. Medicina. 2024; 60(2):197. https://doi.org/10.3390/medicina60020197
Chicago/Turabian StyleFranić, Damir, Maja Franić Ivanišević, and Ivan Verdenik. 2024. "Radiofrequency as the New Opportunity in Treating Overactive Bladder and Urge Urinary Incontinence—A Single-Arm Pilot Study" Medicina 60, no. 2: 197. https://doi.org/10.3390/medicina60020197